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Introduction
The course of bipolar disorder (BD) in women is characterized by increased risk of mood instability during female-reproductive life events such as the premenstrual, perinatal, and perimenopausal periods (1) (2) (3) . The onset of BD in women peaks between 15-23 years of age, with depressive episodes typically preceding manic episodes (4) . Compared to men, women with BD have a higher prevalence of BD type-II, more lifetime number of depressive episodes, rapid cycling, mixed features, and are burdened by more medical and psychiatric comorbidities (5) (6) (7) (8) . While the vast majority of research in women with BD has been in the area of pregnancy and the postnatal period, much fewer studies have examined the relationship between BD and premenstrual dysphoric disorder (PMDD).
PMDD affects 3%-9% of women (9) . PMDD has recently been acknowledged in the DSM-5 as an independent psychiatric diagnosis, whereas in the ICD-10, PMDD is diagnosed under 'Other specified mood (affective) disorders' (10) . A large community-based epidemiological study found that women with a diagnosis of PMDD were eight times more likely to receive a diagnosis of BD, compared to those without PMDD (9) . A longitudinal analysis of the Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD) found that women with BD who reported 'premenstrual worsening of mood' had more depressive episodes, more subthreshold depressive and manic symptoms, and experienced an earlier relapse in the 12-month follow-up (11) . Notably, several independent studies found an association between premenstrual, postnatal, and perimenopausal worsening of symptoms in women with BD (12) (13) (14) , suggesting that a subset of women with BD is particularly vulnerable during periods of hormonal fluctuation (15) . Here, we studied a sample of 1 099 women with BD who provided detailed information on reproductive life events as part of the STEP-BD study (16) .
Aims of the study
The main objective of this study was to compare illness characteristics, prevalence of comorbid psychiatric disorders, and female-specific mental health problems between women with and without premenstrual dysphoric disorder, using the DSM-5 definition. We hypothesized that women with comorbid bipolar disorder and premenstrual dysphoric disorder have a worse course of illness and higher rates of psychiatric morbidity and femalespecific mental health problems.
Material and methods

Participants
Study participants were over 15 years of age and met DSM-IV criteria for bipolar I or bipolar II disorder. To determine a clinical diagnosis, the Mini International Neuropsychiatric Interview (MINI) Plus Version 4.4 (17) and the Affective Disorder Evaluation (ADE) were administered. The ADE is a comprehensive standardized clinical interview, which assesses psychiatric history, current state, diagnosis, most severe episodes, mood symptom pattern, childhood, social and family history, past treatment, and medical history. The ADE contains the mood and psychosis modules derived from the Structured Clinical Interview for DSM-IV (SCID) (18) , and provides a continuous score, which can be used to diagnose bipolar disorder and its subtypes. A final, categorical diagnosis was produced using a consensus of continuous scores on the ADE and categorical MINI diagnosis (19) . Inclusion into the STEP-BD study was offered by psychiatrists to all diagnostically eligible patients in STEP-BD clinics, who met the following criteria: (i) a diagnosis of bipolar disorder I, II, not otherwise specified or cyclothymia through both the MINI and the ADE; (ii) age 15+; (iii) informed consent to enter into the STEP-BD registry. Exclusion criteria consisted of (i) incapability or lack of will to continue with study assessments; (ii) incapability of following informed consent procedures; (iii) patients not being part of the out-patient program (20) . Participants were excluded from the current analysis if they had met criteria for bipolar NOS, cyclothymia or schizoaffective disorder, bipolar subtype. Detailed information about the STEP-BD study is available (16) . Information about past and current premenstrual symptoms was obtained through a self-report questionnaire developed from STEP-BD, which participants completed upon their entrance to the study (11) . The self-report reproductive questionnaire included information about mood symptoms during reproductive events, including 14 premenstrual symptoms (crying easily, food craving, bloating, breast tenderness, feeling overwhelmed or out of control, abdominal pain, lack of energy, decreased interest in activities, irritability/ anger, anxiety/tension, mood swings, depression, insomnia/hypersomnia, and difficulties concentrating), symptoms experienced while taking oral contraceptives, during pregnancy and the postpartum period. It also asked detailed information about participants' early menstrual history, focusing on cycles which occurred during the first 5 years following menarche, and preceded any pregnancy or oral contraceptive consumption. As part of the reproductive questionnaire, participants self-reported having missed their menstrual period for longer than 2 months, other than being pregnant (11) . Research ethics approval was obtained for the study from the Massachussets General Hospital Institutional Review Board. All participants provided written signed informed consent prior to study entry, after receiving a complete description of the study. For participants aged 15-17, written informed consent was obtained from a parent or legal guardian, while written assent was obtained from the participants. The study was registered at ClinicalTrials.-gov. Identifier: NCT00012558.
In this study, we used the new DSM-5 classification criteria to define PMDD diagnosis: at least five symptoms during the premenstrual period, including (i) at least one of the four core symptoms of premenstrual syndrome (PMS) (anxiety/tension, mood swings, depression, and irritability/anger); (ii) other PMS symptoms (crying easily, food cravings, bloating, abdominal pain, breast tenderness, lack of energy, decreased interest in activities, insomnia/hypersomnia, feeling overwhelmed/out of control, and difficulties concentrating); (iii) reporting that the premenstrual symptoms interfered with work, school, activities, and/or interpersonal relationships.
Site selection
Sites for the STEP-BD study were chosen from formal applications, where sites provided information on their capability to provide clinical services, care, and resources to patients with bipolar disorder including the following: availability of staff and clinical services; computer and telecommunication infrastructure appropriate for secure web data entry. The initial screening selected sites in the United States which had specialty bipolar disorder programs, currently caring for at least 100 patients. Of these, the final sites were selected based on experience in conducting research in patients with bipolar disorder, geographic and demographic balance, and diversity criteria, for instance excluding sites that were solely fee-for-service or solely Veteran's Hospital clinics. Prior to initiating the study, selected sites implemented study procedures in the clinic by contracting with the coordinating center. Staff in selected sites were stringently certified in outcome assessment, data entry and medical education in bipolar disorder prior to initiating the study, gathering data, seeing, and treating patients within STEP-BD. The following sites ultimately participated in STEP-BD: Bay- 
Statistical analysis
Statistical analysis was performed using IBM SPSS statistical software, version 22.0.0.0 for Macintosh (21) . The distribution of the data was evaluated using the Shapiro test for normality, and Levene's test for equality of variances. We used independent t-tests to compare continuous variables between women with and without PMDD for normally distributed variables. For non-parametric variables, we used the Mann-Whitney U-test to compare continuous variables between groups. To compare categorical variables between women with and without PMDD, including demographics and illness comorbidities, we performed chi-square tests and calculated odds ratios. We conducted a logrank test to compare age of onset for bipolar disorder between women with and without PMDD and to evaluate the gap between menarche and onset of bipolar disorder. We created Kaplan-Meier survival curves, and compared these using the logrank test, to determine whether these were statistically different. To test whether the history of PMDD had an independent effect on risk of psychiatric comorbidities, rapid cycling, number of episodes, and antidepressant-induced mania, we performed binomial and multinomial logistic regression analyses. Binomial logistic regressions were used for binary outcomes (psychiatric comorbidity, rapid cycling, and antidepressant-induced mania). Each regression included age of onset of BD and PMDD diagnosis. Multinomial logistic regressions were used to analyze non-binary outcomes: total number of episodes (lifetime and past year), and number of hypo/manic and depressive episodes (lifetime and past year). The STEP-BD study collected information on number of episodes categorically. Lifetime and past-year total number of episodes was described in categories: (0, 1, 2, 3, 4, 5-12, 13-52, and 53+). Data concerning lifetime number of hypo/manic and depressive episodes were collected in the following categories: (0, 1, 2, 3-4, 5-9, 10-20, 20-50, and too many to count). Finally, data concerning past-year number of depressive and hypo/manic episodes were collected as a continuous measure. Due to the use of these discrepant categories, we standardized this information into a smaller number of categories which were more comparable between lifetime and past-year number of episodes. Total number of past-year and lifetime episodes was categorized according to number of episodes (0, 1, 2-12, and 13+), as were past-year and lifetime hypo/manic and depressive episodes (0, 1, 2-9, and 10+). In these multinomial regressions, we controlled for age of onset and lifetime comorbidities which were significantly associated with PMDD. All tests were performed using a = 0.05 as the level of significance.
Results
Demographics
We studied 1 099 women with a diagnosis of bipolar I or bipolar II disorder who completed the self-report reproductive questionnaire (11) . There were no differences in age, race, marital status, or employment status between women with or without PMDD (P > 0.05, Table 1 ). Women with comorbid PMDD had achieved a lesser level of education than women with no PMDD (P = 0.03).
Illness characteristics
Women with and without PMDD were equally likely to have bipolar I or II disorder and did not differ in terms of first episode polarity ( Table 2 ). Women with PMDD had an earlier age of onset compared to women without PMDD (14.6 AE 6.4 vs. 16.7 AE 7.6, P < 0.001, Fig. 1a) , including earlier onset of both hypo/manic and depressive episodes (P < 0.001). In unadjusted analyses, women with PMDD were more likely to report rapid cycling (OR = 1.94, 95% CI: 1.44, 2.62), antidepressant-induced mania (OR = 1.31, 95% CI: 1.02, 1.69), as well as greater number of depressive and hypo/manic episodes both lifetime and in the past year (P < 0.01). However, after controlling for age of onset and psychiatric comorbidities, presence of PMDD was still associated with higher risk of rapid cycling (OR = 1.43, 95% CI: 1.02, 2.01), but the differences in antidepressant-induced mania and total number of lifetime and past-year mood episodes were no longer significant. Women with comorbid PMDD had higher number of past-year hypo/manic (P = 0.003) and lifetime/past-year depressive episodes (P < 0.05).
Psychiatric comorbidities
Women with comorbid PMDD were more likely to have a lifetime history of an anxiety disorder (OR = 2.10, 95% CI: 1.61, 2.72, Fig. 2 
Female-specific mental health
Women with comorbid PMDD reported earlier age of menarche (P = 0.015). Notably, there was shorter span of time between the age of menarche and the onset of BD in women with PMDD (P < 0.003, Table 2 , Fig. 1b ). As far as a possible link with other periods of intense hormonal fluctuation, women with PMDD were more likely to report severe mood symptoms during pregnancy (OR = 2.38, 95% CI: 1.73, 3.28) and in the postnatal period (OR = 1.92, 95% CI: 1.35, 2.72) compared to women without PMDD. Finally, women with PMDD were more likely to report severe mood symptoms while taking oral contraceptives (OR = 2.60, 95% CI: 1.97, 3.43). Women with and without PMDD were equally likely to report a history of having missed their menstrual period for more than 2 months, excluding pregnancies (OR = 0.93, 95% CI: 0.73, 1.18). GED, general education diploma; PMDD, premenstrual dysphoric disorder; SD, standard deviation; Sig., significance; STEP-BD, systematic treatment enhancement program for bipolar disorder. Fig. 2 . Psychiatric comorbidities in women with and without premenstrual dysphoric disorder comorbid with bipolar disorder ***P < 0.001, **P < 0.01, *P < 0.05. Abbreviations: PMDD = premenstrual dysphoric disorder; OCD = obsessive-compulsive disorder. [Colour figure can be viewed at wileyonlinelibrary.com]
Discussion
Illness characteristics
One of the most important findings of this study is that women with comorbid PMDD had an earlier age of onset of BD. Given that earlier age at onset has been widely associated with worse clinical and functional outcomes in BD, this suggests that the comorbidity with PMDD is associated with increased illness burden. We also found that women with PMDD have higher rates of rapid cycling and more past-year hypo/manic and pastyear/lifetime depressive episodes. While the literature is inconsistent in terms of increased risk of rapid cycling, with both positive (22) and negative (12) findings, our results are consistent with a previous report of an earlier age onset in women with BD and premenstrual syndrome (23) . Our study suggests that women with comorbid PMDD may represent a subtype of individuals with higher sensitivity to mood instability associated with fluctuation of endogenous hormones (13, 15) . A recent study of 158 women with BD found that an earlier age of onset was associated with mood worsening during reproductive life events and that earlier onset of depressive episodes was linked to more mood instability during use of oral contraceptives (13) .
Psychiatric comorbidities
We found that women with comorbid PMDD had higher rates of other psychiatric disorders, including panic disorder, GAD, PTSD, lifetime alcohol and drug abuse, bulimia, and adult ADHD (Fig. 2) .
Our results are inconsistent with a small study of 92 women with BD that did not find differences in comorbidity of GAD, panic disorder, agoraphobia, anorexia, bulimia, alcohol, or substance abuse (12) . Also contrary to our study, this latter study reported higher rates of OCD in women with BD and comorbid PMDD (12) . The association of premenstrual symptoms and substance use has been previously reported in a cohort of women with PMS (24) and in a community-based cohort where illicit substance use preceded the onset of PMS (25) . A novel finding in our sample is that women with comorbid PMDD were more likely to be diagnosed with adult ADHD. Although previous studies have pointed to cognitive deficits associated with PMDD (e.g. 26) , this association, to our knowledge, has not been reported in any population.
Eating disorders are highly prevalent among women with BD. Bulimia nervosa has a 15% prevalence among individuals with BD, while a further 12% report binge eating disorder, and 0.2% report anorexia nervosa (27) , compared to the 0.9% and 1.5% lifetime prevalence of anorexia and bulimia nervosa in the US respectively (28) . Interestingly, a recent large epidemiological study (N = 8 694) found that women with PMDD were 89 more likely to receive a diagnosis of bulimia nervosa (29) .
Female-specific mental health
A novel finding of our study was that women with comorbid PMDD had an earlier age at menarche, and perhaps more importantly, the age of onset of BD was closer to the menarche in women with PMDD compared to those without PMDD. Previous smaller studies have supported an association between onset of BD and menarche (30) , and if our result is replicated in an independent large study this may open a venue for research on the role of hormones/puberty on the onset of BD.
We also found that women with comorbid PMDD reported greater mood instability during pregnancy, postnatal period, and use of hormonal contraceptives, which suggests that these women may represent a particular subtype with increased vulnerability to mood worsening during periods of intense hormonal fluctuation. Previously, Payne and colleagues did not find an association between premenstrual symptoms and postpartum symptoms in women with bipolar I disorder, although this association was present in women with major depressive disorder (31) . More recently, Fornaro & Perugi (12) found that history of postnatal depression was associated with diagnosis of PMDD among women with BD, consistent with Perich et al. (13) who also found a link between postnatal mood episodes and premenstrual symptom worsening in women with BD. Our finding that women with comorbid PMDD are more likely to report severe mood symptoms while using hormonal contraceptives is a novel finding. The literature on the impact of hormonal contraceptives in women with BD is scant and inconsistent. For instance, Freeman et al. (32) did not find an association between contraceptive agents and mood worsening in a sample of 50 women with BD, while Perich et al. (13) found that 35% of women with BD reported worsening of mood symptoms associated with contraceptive use. Finally, we have recently published clinical cases of women with comorbid BD and PMDD who responded well to hormonal contraceptives adjunctive to mood stabilizers for treatment of PMDD (33, 34) .
Strengths and limitations
One of the strengths of this study is the sample size (n = 1 099). To our knowledge, this is the largest study investigating the burden of illness in women with comorbid BD and PMDD. Another strength was the careful clinical characterization of the study population that allowed us to investigate the rates of other comorbid psychiatric disorders. Also, the use of a detailed questionnaire of reproductive life events allowed us to define the PMDD cases based on the DSM-5 criteria. In terms of limitations, this study was a post hoc analysis and was not originally designed to investigate the impact of comorbid PMDD in women with BD. Mood symptoms and history of past manic and depressive episodes were obtained through self-report and were, therefore, subject to recall bias. Moreover, our study design did not enable us to confirm the presence of premenstrual symptoms through prospective symptom charting, as per the current standards of PMDD diagnosis. However, the DSM-5 criteria allow the diagnosis of 'provisional PMDD' before the prospective evaluation of symptoms is completed, and it is very unlikely that any study with a sample size in the range of thousands will be able to conduct daily prospective symptom charting. In fact, the challenge of prospective data collection in large cohorts of women with PMDD is well documented, where less than half of women tend to complete the prospective charting required for a formal diagnosis (35) . Additionally, the STEP-BD study collected information on number of episodes categorically, where lifetime and past-year total number of episodes and lifetime number of manic and depressive episodes were collected using different categorization, whereas data concerning pastyear number of depressive and manic episodes were collected as a continuous measure. This discrepancy may explain why we found differences between women with and without PMDD in pastyear hypo/manic episodes and lifetime and pastyear depressive episodes, but not in total lifetime and past-year number of episodes. Finally, the cohort of women in STEP-BD mostly consisted of Caucasian women (88.7%), which limits our ability to generalize these results cross-culturally.
In summary, our results support converging evidence suggesting that some women with BD might be particularly vulnerable to mood instability during periods of intense hormonal fluctuation. The closer gap between age of menarche and the onset of BD in women with comorbid PMDD is intriguing and should stimulate future research to identify the women at higher risk.
